Cargando…
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288767/ http://dx.doi.org/10.1186/2051-1426-2-S3-P89 |
_version_ | 1782352020571684864 |
---|---|
author | Chow, Shien Evans, Manon Galvis, Victoria Leach, Rebecca Keene, Elizabeth Chan, Kevin Spencer-Shaw, Andrea Jonathan, Shanks Shabalak, Alaaeldin Thistlethwaite, Fiona Hawkins, Robert |
author_facet | Chow, Shien Evans, Manon Galvis, Victoria Leach, Rebecca Keene, Elizabeth Chan, Kevin Spencer-Shaw, Andrea Jonathan, Shanks Shabalak, Alaaeldin Thistlethwaite, Fiona Hawkins, Robert |
author_sort | Chow, Shien |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-4288767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42887672015-01-15 High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection Chow, Shien Evans, Manon Galvis, Victoria Leach, Rebecca Keene, Elizabeth Chan, Kevin Spencer-Shaw, Andrea Jonathan, Shanks Shabalak, Alaaeldin Thistlethwaite, Fiona Hawkins, Robert J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288767/ http://dx.doi.org/10.1186/2051-1426-2-S3-P89 Text en Copyright © 2014 Chow et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Poster Presentation Chow, Shien Evans, Manon Galvis, Victoria Leach, Rebecca Keene, Elizabeth Chan, Kevin Spencer-Shaw, Andrea Jonathan, Shanks Shabalak, Alaaeldin Thistlethwaite, Fiona Hawkins, Robert High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection |
title | High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection |
title_full | High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection |
title_fullStr | High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection |
title_full_unstemmed | High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection |
title_short | High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection |
title_sort | high-dose interleukin-2 (hd-il2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection |
topic | Poster Presentation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288767/ http://dx.doi.org/10.1186/2051-1426-2-S3-P89 |
work_keys_str_mv | AT chowshien highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT evansmanon highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT galvisvictoria highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT leachrebecca highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT keeneelizabeth highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT chankevin highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT spencershawandrea highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT jonathanshanks highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT shabalakalaaeldin highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT thistlethwaitefiona highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection AT hawkinsrobert highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection |